One of the stumbling blocks to development of a live-attenuated RSV vaccine is induction of long-lasting immunity, which does not occur even with wild-type RSV infection. Since induction of robust adaptive immunity responses requires a strong innate immune activation, the short-lived anti-RSV response may be due to viral inhibition of type I interferon (IFN) induction. Antagonism of IFN production is largely due to the RSV NS1 protein, which is not absolutely essential for virus replication in culture although deletion of NS1 results in decreased viral replication even in IFN-deficient cells such as Vero. This proposal will identify domains and/or specific residues of NS1 responsible for IFN antagonism by targeted mutagenesis. Mutants that ablate the IFN antagonist function without affecting protein stability will be inserted into recombinant RSV (rRSV) and tested for their capacity to replicate in Vero cells and induce IFN in A549 cells. NS1 mutant rRSV that induce high levels of IFN expression and replicate well in these cell lines will be tested for IFN antagonism and replication in human airway epithelial (HAE) cultures. Further, the NS1 mutant rRSV will be tested in cotton rats, which are the best small animal model for RSV infection to determine replication in vivo, pathogenicity, immunogenicity, and protection from WT challenge. The best candidate NS1 mutants will be combined with the `repaired' G gene (Project 2) and the best attenuating L methyltransferase (MTase) mutations (Project 3) to produce double and triple mutant viruses that replicate well in Vero cells, induce high levels of IFN, efficiently infect HAE culture, and are attenuated and protective in cotton rats. Although beyond the scope of this P01, these vaccine candidates will be tested in non-human primate trials in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI112524-03
Application #
9217571
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2015-08-27
Project End
2020-01-31
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Nationwide Children's Hospital
Department
Type
DUNS #
147212963
City
Columbus
State
OH
Country
United States
Zip Code
43205
Hussain, Syed-Rehan A; Mejias, Asuncion; Ramilo, Octavio et al. (2018) Post-viral atopic airway disease: pathogenesis and potential avenues for intervention. Expert Rev Clin Immunol :1-10
Garcia-Mauriño, Cristina; Moore-Clingenpeel, Melissa; Wallihan, Rebecca et al. (2018) Discharge Criteria for Bronchiolitis: An Unmet Need. Pediatr Infect Dis J 37:514-519
Wang, Yilong; Liu, Rongxian; Lu, Mijia et al. (2018) Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein. Virology 518:210-220
Li, Anzhong; Yu, Jingyou; Lu, Mijia et al. (2018) A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat Commun 9:3067
Korppi, Matti (2018) Discharge Criteria for Bronchiolitis: Does Age Matter? Pediatr Infect Dis J 37:e350
Garcia-Mauriño, Cristina; Moore-Clingenpeel, Melissa; Ramilo, Octavio et al. (2018) Re: ""Discharge Criteria for Bronchiolitis: Does Age Matter?"" Pediatr Infect Dis J 37:e350-e351
Grieves, Jessica L; Yin, Zhiwei; Garcia-Sastre, Adolfo et al. (2018) A viral-vectored RSV vaccine induces long-lived humoral immunity in cotton rats. Vaccine 36:3842-3852
Garcia-Mauriño, Cristina; Moore-Clingenpeel, Melissa; Thomas, Jessica et al. (2018) Viral Load Dynamics and Clinical Disease Severity in Infants with Respiratory Syncytial Virus Infection. J Infect Dis :
Mazur, Natalie I; Higgins, Deborah; Nunes, Marta C et al. (2018) The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 18:e295-e311
Hicks, Stephanie N; Chaiwatpongsakorn, Supranee; Costello, Heather M et al. (2018) Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F2 Subunit Are Critical for Its Fusion Activity. J Virol 92:

Showing the most recent 10 out of 21 publications